Table 4 Outcomes of older patients with acute myeloid leukemia assigned to the genetic groups
From: A precision medicine classification for treatment of acute myeloid leukemia in older patients
Outcome | CBF n = 74 | NPM1m/FLT3-ITD- n = 107 | KMT2A n = 13 | IDH2m n = 59 | IDH1m n = 35 | TP53m n = 50 | Complex karyotype/ TP53wt n = 28 | FLT3m n = 99 | TET2m or WT1m n = 42 | Marker-negative n = 56 |
|---|---|---|---|---|---|---|---|---|---|---|
CR | 55 (74) | 73 (68) | 8 (62) | 24 (41) | 14 (40) | 8 (16) | 9 (32) | 47 (47) | 16 (38) | 22 (39) |
Early death, n (%) | 0 (0) | 21 (20) | 3 (23) | 11 (19) | 8 (23) | 21 (42) | 5 (18) | 23 (23) | 7 (17) | 11 (20) |
Death in CR, n (%) | 6 (11) | 4 (5) | 3 (38) | 1 (4) | 1 (7) | 0 (0) | 0 (0) | 9 (19) | 0 (0) | 1 (5) |
Relapse rate, n (%) | 34 (62) | 59 (81) | 5 (63) | 23 (96) | 13 (93) | 8 (100) | 9 (100) | 37 (79) | 16 (100) | 18 (82) |
Number expired, n (%) | 56 (76) | 95 (89) | 13 (100) | 59 (100) | 35 (100) | 50 (100) | 28 (100) | 97 (98) | 42 (100) | 52 (93) |
Disease-free survival (DFS) | ||||||||||
 Median (years) (95% CI) | 0.9 (0.7–1.9) | 1.0 (0.8–1.2) | 0.5 (0.1–0.7) | 0.9 (0.4–1.8) | 0.6 (0.3–1.2) | 0.4 (0.2–0.4) | 0.4 (0.1–0.5) | 0.5 (0.3–0.6) | 0.7 (0.5–0.9) | 0.7 (0.4–1.0) |
 % Disease-free at 1 y (95% CI) | 48 (35–61) | 53 (41–64) | 13 (1–42) | 46 (26–64) | 29 (9–52) | 0 | 11 (1–39) | 15 (7–27) | 13 (2–33) | 41 (21–60) |
 % Disease-free at 3 y (95% CI) | 30 (18–42) | 27 (18–38) | 0 | 8 (1–23) | 0 | 0 | 0 | 7 (2–16) | 0 | 14 (3–31) |
 % Disease-free at 5 y (95% CI) | 30 (18–42) | 22 (13–32) | 0 | 4 (0–18) | 0 | 0 | 0 | 7 (2–16) | 0 | 14 (3–31) |
Overall survival (OS) | ||||||||||
 Median (years) (95% CI) | 1.5 (1.0–2.0) | 1.3 (1.0–1.5) | 0.5 (0–0.8) | 0.6 (0.4–0.9) | 0.6 (0.2–0.8) | 0.2 (0.1–0.3) | 0.2 (0.1–0.5) | 0.5 (0.4–0.6) | 0.6 (0.4–0.9) | 0.7 (0.3–1.1) |
 % Alive at 1 y (95% CI) | 61 (48–71) | 59 (49–68) | 8 (0–29) | 36 (24–48) | 23 (11–38) | 0 | 21 (9–38) | 18 (11–26) | 31 (18–45) | 39 (27–52) |
 % Alive at 3 y (95% CI) | 33 (23–44) | 27 (19–36) | 0 | 15 (8–26) | 6 (1–17) | 0 | 7 (1–20) | 7 (3–13) | 0 | 9 (3–18) |
 % Alive at 5 y (95% CI) | 30 (20–41) | 21 (14–29) | 0 | 8 (3–17) | 3 (0–13) | 0 | 0 | 5 (2–11) | 0 | 7 (2–16) |